Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy ; volume:43 ; number:1 ; day:2 ; month:9 ; year:2024 ; pages:1-14 ; date:12.2024
Journal of experimental & clinical cancer research ; 43, Heft 1 (2.9.2024), 1-14, 12.2024
- Urheber
-
He, Kewen
Puebla-Osorio, Nahum
Barsoumian, Hampartsoum B.
Sezen, Duygu
Rafiq, Zahid
Riad, Thomas S.
Hu, Yun
Huang, Ailing
Voss, Tiffany A.
Leyton, Claudia S. Kettlun
Schuda, Lily Jae
Hsu, Ethan
Heiber, Joshua
Cortez, Maria-Angelica
Welsh, James W.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-024-03165-x
- URN
-
urn:nbn:de:101:1-2411252109419.823945314903
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- He, Kewen
- Puebla-Osorio, Nahum
- Barsoumian, Hampartsoum B.
- Sezen, Duygu
- Rafiq, Zahid
- Riad, Thomas S.
- Hu, Yun
- Huang, Ailing
- Voss, Tiffany A.
- Leyton, Claudia S. Kettlun
- Schuda, Lily Jae
- Hsu, Ethan
- Heiber, Joshua
- Cortez, Maria-Angelica
- Welsh, James W.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
Boosting antitumor drug efficacy with chemically engineered multidomain proteins
Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins
Regulatory T cells in immune checkpoint blockade antitumor therapy
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy
Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector
Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
Boosting antitumor drug efficacy with chemically engineered multidomain proteins
Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins
Regulatory T cells in immune checkpoint blockade antitumor therapy
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy
Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector
Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer
PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
Boosting antitumor drug efficacy with chemically engineered multidomain proteins
Boosting Antitumor Drug Efficacy with Chemically Engineered Multidomain Proteins
Regulatory T cells in immune checkpoint blockade antitumor therapy
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy